SCHEMBL215228

SCHEMBL215228

Cc1ccc(Br)cc1-n1cnc(C(N)=O)c1C(=O)Nc1ccc(Cl)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 1/20 0.44
KMT2A Q03164 5/20 0.41
RAB9A P51151 5/20 0.41
NPC1 O15118 4/20 0.41
ALDH1A1 P00352 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
LMNA P02545 1/20 0.41
GAA P10253 1/20 0.41
MEN1 O00255 3/20 0.41
RXFP1 Q9HBX9 1/20 0.41
KDM4E B2RXH2 2/20 0.40
MAPK1 P28482 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
NR3C1 P04150 1/20 0.40
IDH1 O75874 1/20 0.39
TP53 P04637 1/20 0.37
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL213975 0.92 KMT2A (0.42) KMT2ARAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL214574 0.90 RAB9A (0.41) KMT2ARAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL215860 0.90 MEN1 (0.38) SCN9AKMT2ARAB9ANPC1ALDH1A1
SCHEMBL215824 0.90 RAB9A (0.41) KMT2ARAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL215330 0.89 ALDH1A1 (0.46) KMT2ARAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL214745 0.88 KMT2A (0.41) SCN9AKMT2ARAB9ANPC1ALDH1A1
SCHEMBL214245 0.88 NPC1 (0.41) KMT2ARAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL213700 0.85 SORT1 (0.46) KMT2ARAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL214029 0.82 MAPT (0.46) KMT2ARAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL214660 0.82 SIK1 (0.33) KMT2ARAB9AMEN1RXFP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US disclosed
EP-2061768-A2 IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS Exelixis, Inc. (US) 2009-05-27 EP disclosed
WO-2008042282-A2 IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS EXELIXIS, INC. (US) 2008-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100136136-A1 JAK-2 Modulators and Methods of Use JAK2, JAK1, JAK3 SCN9A 3536/4885KMT2A 437/4885RAB9A 2213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.